University of North Carolina, Lineberger Comprehensive Cancer Center | Strategic Alliance Partners

Latest from University of North Carolina, Lineberger Comprehensive Cancer Center


FOLFOX Produces Varying Toxicity Profile vs Chemoradiation in Rectal Cancer

July 01, 2023

Lower rates of diarrhea and overall bowel dysfunction were reported with the use of neoadjuvant fluorouracil and oxaliplatin vs neoadjuvant pelvic chemoradiation with fluorouracil (5FCURT) in patients with locally advanced rectal cancer. However, lower rates of other toxicities were reported in patients treated with 5FCURT.

RxPONDER Analysis Reveals Racial Disparities in HR+/HER2– Breast Cancer

February 15, 2023

Yara Abdou, MD, discusses the racial and clinical analysis of the RxPONDER trial, the need to further investigate the factors that create racial disparities in breast cancer, and the importance of enrolling minority populations onto clinical trials.

Breast Cancer Expert Focuses on Decoding Biomarkers

February 02, 2023

For Kevin Kalinsky, MD, MS, director of breast medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, his work on the RxPONDER trial serves as one of a few accomplishments for which he is grateful that have impacted clinical care.

PDS0101 Shows Synergistic Activity With Pembrolizumab in HPV16+ Head and Neck Squamous Cell Carcinoma

June 07, 2022

The combination of PDS0101 and pembrolizumab led to encouraging responses and favorable safety with no grade 3 or greater treatment-related adverse effects in patients with checkpoint inhibitor–naïve HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma, according to findings from a prespecified interim analysis of the phase 2 VERSATILE-002 study.

Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL

January 17, 2022

Dr Coombs discusses research that was presented at the 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.

Adagrasib With or Without Cetuximab Produces Encouraging Clinical Activity in KRAS G12C–Mutant CRC

January 13, 2022

Jared Weiss, MD, sheds light on the exploration of adagrasib as a monotherapy and in combination with cetuximab in patients with KRAS G12C–mutated metastatic colorectal cancer, key findings from the KRYSTAL-1 study, and next steps for research.

Coombs Previews Anticipated ASH Abstracts in CLL

December 09, 2021

Dr. Coombs discusses research that will be presented at the upcoming 2021 ASH Annual Meeting and Exposition in chronic lymphocytic leukemia, including that with covalent and noncovalent BTK inhibitors, COVID-19 vaccinations, and time-limited combinations.